Organofluorides

Eisai to Launch In-House Developed New Anti-insomnia Drug Dayvigo (Lemborexant) with Indication for Insomnia in Japan

Retrieved on: 
Monday, July 6, 2020
Branches of biology, Chemical compounds, Biology, Molecular neuroscience, Hypnotics, Cyclopropanes, Lemborexant, Organofluorides, Pyrimidines, Eisai, Insomnia, Sleep onset

2.5 mg, 5 mg, 10 mg tablets (lemborexant) for treatment of insomnia in Japan on July 6, 2020.

Key Points: 
  • 2.5 mg, 5 mg, 10 mg tablets (lemborexant) for treatment of insomnia in Japan on July 6, 2020.
  • DAYVIGO acts on the orexin neurotransmitter system and is believed to facilitate sleep onset, sleep maintenance, and wake by regulating sleep-wake rhythm.
  • (9)
    Through the launch of DAYVIGO, Eisai will continue to prioritize the provision of appropriate usage and safety information.
  • For more information about Eisai Co., Ltd., please visit https://www.eisai.com
    Public Relations Department Eisai Co., Ltd. +81-(0)3-3817-5120
    Copyright 2020 JCN Newswire .

Global Fluoropolymers Market Assessment 2007-2025 - Trends & Opportunities, Consumption & Production, Imports & Exports, Price Developments, Major Producers - ResearchAndMarkets.com

Retrieved on: 
Friday, July 3, 2020
Chemicals, Plastics, Manufacturing, Market research, Fluoropolymer, Organofluorides, Polymers, Thermoplastics, Domain driven data mining, Market analysis, Economy

The "World - Fluoropolymers - Market Analysis, Forecast, Size, Trends and Insights" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "World - Fluoropolymers - Market Analysis, Forecast, Size, Trends and Insights" report has been added to ResearchAndMarkets.com's offering.
  • This report provides an in-depth analysis of supply and demand for fluoropolymers on the global market.
  • It will help you to find actionable insights and make data-driven decisions for growing your business.
  • This report contains the latest data on market trends and opportunities, consumption, production, imports, exports and price developments.

Akero Announces Strongly Positive Histological Data Across All Efruxifermin Dose Groups in 16-Week Phase 2a BALANCED Study in NASH Patients

Retrieved on: 
Tuesday, June 30, 2020
Pyrimidines, Organofluorides, Antibodies, Bristol-Myers Squibb, Clazakizumab, Chemistry, Palifermin

We are extremely grateful to all of our investigators and study patients, particularly given that this study cohort was completed amidst the COVID-19 pandemic."

Key Points: 
  • We are extremely grateful to all of our investigators and study patients, particularly given that this study cohort was completed amidst the COVID-19 pandemic."
  • The BALANCED study is an ongoing randomized, double-blind, placebo-controlled study in NASH patients.
  • The Phase 2a BALANCED study is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging trial in biopsy-confirmed adult patients with NASH.
  • Efruxifermin (EFX), formerly known as AKR-001, is Akero's lead product candidate for NASH, currently being evaluated in the ongoing Phase 2a BALANCED study.

Zhejiang Hisun Pharmaceutical Co. Ltd.: Free of COVID-19, Governments Suggest Favipiravir

Retrieved on: 
Tuesday, June 30, 2020
Organic compounds, Ebola, Antivirals, Drugs, Chemistry, Favipiravir, Hydroxyarenes, Organofluorides, Pyrazines, Remdesivir, Antiviral drug, Virus

Unlike traditional antiviral drugs, Favipiravir can directly prevent the virus from replicating itself in cells, with a mechanism of action similar to Remdesivir.

Key Points: 
  • Unlike traditional antiviral drugs, Favipiravir can directly prevent the virus from replicating itself in cells, with a mechanism of action similar to Remdesivir.
  • Since the outbreak of COVID-19, the Chinese and Japanese governments have strongly recommended use of Favipiravir to treat the disease.
  • Originally developed by Toyama Chemical Co., Ltd., Favipiravir was approved as strategic stockpile as a countermeasure for virus in Japan.
  • In 2016, the patent of Favipiravir was exclusively franchised to Zhejiang Hisun Pharmaceutical Co., Ltd. (HISUN), which cooperated with CMAM to develop Favipiravir tablets.

Zhejiang Hisun Pharmaceutical Co. Ltd.: Free of COVID-19, Governments Suggest Favipiravir

Retrieved on: 
Tuesday, June 30, 2020
Organic compounds, Ebola, Antivirals, Drugs, Chemistry, Favipiravir, Hydroxyarenes, Organofluorides, Pyrazines, Remdesivir, Antiviral drug, Virus

Unlike traditional antiviral drugs, Favipiravir can directly prevent the virus from replicating itself in cells, with a mechanism of action similar to Remdesivir.

Key Points: 
  • Unlike traditional antiviral drugs, Favipiravir can directly prevent the virus from replicating itself in cells, with a mechanism of action similar to Remdesivir.
  • Since the outbreak of COVID-19, the Chinese and Japanese governments have strongly recommended use of Favipiravir to treat the disease.
  • Originally developed by Toyama Chemical Co., Ltd., Favipiravir was approved as strategic stockpile as a countermeasure for virus in Japan.
  • In 2016, the patent of Favipiravir was exclusively franchised to Zhejiang Hisun Pharmaceutical Co., Ltd. (HISUN), which cooperated with CMAM to develop Favipiravir tablets.

Zhejiang Hisun Pharmaceutical Co., Ltd.: Free of COVID-19, Governments Suggest Favipiravir

Retrieved on: 
Friday, June 26, 2020
Infectious diseases, Pharmaceutical, Health, Clinical trials, Organic compounds, Ebola, Antivirals, Drugs, Chemistry, Favipiravir, Hydroxyarenes, Organofluorides, Pyrazines, Remdesivir, Virus, Antiviral drug

Unlike traditional antiviral drugs, Favipiravir can directly prevent the virus from replicating itself in cells, with a mechanism of action similar to Remdesivir.

Key Points: 
  • Unlike traditional antiviral drugs, Favipiravir can directly prevent the virus from replicating itself in cells, with a mechanism of action similar to Remdesivir.
  • View the full release here: https://www.businesswire.com/news/home/20200626005456/en/
    Since the outbreak of COVID-19, the Chinese and Japanese governments have strongly recommended use of Favipiravir to treat the disease.
  • Originally developed by Toyama Chemical Co., Ltd., Favipiravir was approved as strategic stockpile as a countermeasure for virus in Japan.
  • In 2016, the patent of Favipiravir was exclusively franchised to Zhejiang Hisun Pharmaceutical Co., Ltd. (HISUN), which cooperated with CMAM to develop Favipiravir tablets.

CHMP Grants Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With KALYDECO® (ivacaftor) in People Ages 12 and Older With Cystic Fibrosis With the Most Common Genotypes

Retrieved on: 
Friday, June 26, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical trials, Chemical compounds, Chemistry, Organic compounds, Breakthrough therapy, Cyclopropanes, Organofluorides, Ivacaftor, Phenols, Tezacaftor, Cystic fibrosis transmembrane conductance regulator, Pulmonology, Pediatrics, Cystic Fibrosis, KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a Combination Regimen With KALYDECO® (ivacaftor)

In both studies, the ivacaftor/tezacaftor/elexacaftor plus ivacaftor combination regimen was generally well tolerated.

Key Points: 
  • In both studies, the ivacaftor/tezacaftor/elexacaftor plus ivacaftor combination regimen was generally well tolerated.
  • The clinical data for ivacaftor/tezacaftor/elexacaftor plus ivacaftor in people with CF ages 12 years and older with an F/F or F/MF genotype are unprecedented.
  • Mall, M.D., Head of Department of Pediatric Pulmonology, Immunology and Critical Care Medicine at Charit University Medical Center Berlin.
  • Both the clinical and patient communities are excited that more people with CF will be able to benefit from CFTR modulators.

New Scorecard: Supermarkets Failing to Tackle Super Pollutant HFCs

Retrieved on: 
Thursday, June 25, 2020
Construction & Property, Supermarket, Other Policy Issues, Building Systems, Utilities, Retail, Oil, Gas, Alternative energy, Public policy, Government, Environment, Energy, Food and drink, High-fructose corn syrup, Starch, Climate change policy, Organofluorides, Politics of climate change

Although climate-friendly options are readily available, American supermarkets continue to rely on HFCs with thousands of times the climate impact of CO2.

Key Points: 
  • Although climate-friendly options are readily available, American supermarkets continue to rely on HFCs with thousands of times the climate impact of CO2.
  • This scorecard reveals that shockingly few supermarkets use HFC-free systems and their efforts to reduce HFC emissions are woefully inadequate.
  • The highest grossing supermarkets on this list have the power to help solve the climate crisis.
  • Instead, they are exacerbating the problem - continuing to use and leak super pollutant HFCs, said Avipsa Mahapatra, EIA Climate Campaign Lead.

Vizient Data Show 610% Increase in Demand for Dexamethasone after Study Shows Effectiveness for Patients Severely Ill with COVID-19

Retrieved on: 
Thursday, June 25, 2020
Medical Supplies, Health, Infectious diseases, Hospitals, Practice Management, Clinical trials, Pharmaceutical, RTT, Drugs, Glucocorticoids, Pregnanes, Dexamethasone, Organofluorides, Otologicals, Cancer, Chemistry, Medicine

As a result of the spike in demand, fill rates for the products are now at 54% for Vizient member hospitals.

Key Points: 
  • As a result of the spike in demand, fill rates for the products are now at 54% for Vizient member hospitals.
  • Now, six days later, aggregated demand is up 610% and the fill rate has dropped from 97% to 54%.
  • Dexamethasone has been used since the 1960s to reduce inflammation in a range of conditions, including inflammatory disorders and certain cancers.
  • Dexamethasone is a workhorse drug for hospitals and it is good that there are several manufacturers in the supply chain.

Hisun Pharmaceutical: Free of COVID-19, Governments Suggest Favipiravir

Retrieved on: 
Tuesday, June 23, 2020
Organic compounds, Ebola, Antivirals, Drugs, Chemistry, Favipiravir, Hydroxyarenes, Organofluorides, Pyrazines, Remdesivir, Antiviral drug, Virus

Unlike traditional antiviral drugs, Favipiravir can directly prevent the virus from replicating itself in cells, with a mechanism of action similar to Remdesivir.

Key Points: 
  • Unlike traditional antiviral drugs, Favipiravir can directly prevent the virus from replicating itself in cells, with a mechanism of action similar to Remdesivir.
  • Since the outbreak of COVID-19, the Chinese and Japanese governments have strongly recommended use of Favipiravir to treat the disease.
  • Originally developed by Toyama Chemical Co., Ltd., Favipiravir was approved as strategic stockpile as a countermeasure for virus in Japan.
  • In 2016, the patent of Favipiravir was exclusively franchised to Zhejiang Hisun Pharmaceutical Co., Ltd. (HISUN), which cooperated with CMAM to develop Favipiravir tablets.